Belize vs Lebanon: HIV/AIDS deaths averted by antiretroviral therapy
Belize
87.27 deaths
in 2024
Lebanon
101 deaths
in 2022
Belize rank
127th
Lebanon rank
125th
HIV/AIDS deaths averted by antiretroviral therapy over time
- Belize
- Lebanon
How they compare
Lebanon currently reports 101 deaths against 87.27 deaths in Belize, a difference of 13.73 deaths.
That makes Lebanon's figure about 1.2 times Belize's.
The two have swapped places 2 times across 33 shared years of data; in 1990 it was Lebanon ahead.
Belize ranks 127th and Lebanon ranks 125th of 157 countries.
Across the 4 decades both report, Belize averaged higher in 2 and Lebanon in 1.
Head to head by decade
| Decade | Belize | Lebanon | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 0 deaths | 0 deaths | 0 deaths | — |
| 2000s | 40.13 deaths | 23.6 deaths | 16.53 deaths | Belize |
| 2010s | 94.11 deaths | 68.4 deaths | 25.71 deaths | Belize |
| 2020s | 68.77 deaths | 98.67 deaths | 29.9 deaths | Lebanon |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hiv/aids deaths averted by antiretroviral therapy, Belize or Lebanon?
- Lebanon, at 101 deaths against 87.27 deaths in Belize as of 2022.
- What is the difference in hiv/aids deaths averted by antiretroviral therapy between Belize and Lebanon?
- 13.73 deaths, with Lebanon ahead.
- How many years of comparable data are there for Belize and Lebanon?
- 33 years are reported by both, from 1990 to 2022.
- How do Belize and Lebanon rank globally for hiv/aids deaths averted by antiretroviral therapy?
- Belize ranks 127th and Lebanon ranks 125th of 157 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as HIV/AIDS deaths averted by antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of deaths prevented as a direct result of Antiretroviral Therapy (ART) among people living with HIV. It is calculated by comparing the observed mortality rates in individuals receiving ART to the estimated mortality rates in the absence of such treatment. This is the central estimate.